Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 14;38(32):3763–3772. doi: 10.1200/JCO.20.01035

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 2. — Subgroup analysis of objective response rate (ORR) in independent radiology review (IRR)–evaluable population and prostate-specific antigen (PSA) response rate in overall efficacy population by baseline characteristics. Visit cutoff date: December 23, 2019. The vertical dotted line corresponds to the overall ORR or PSA response. (*)One patient received taxane in the hormone-sensitive setting only, which per protocol was not counted as a line of therapy for eligibility; not receiving taxane for castration-resistant prostate cancer was considered a protocol deviation. NA, not applicable.